Wall Street brokerages predict that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at $0.07. Sangamo Therapeutics reported earnings of ($0.15) per share in the same quarter last year, which would indicate a positive year over year growth rate of 13.3%. The company is expected to announce its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.42). For the next year, analysts expect that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.06) to ($0.44). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The firm had revenue of $21.42 million for the quarter, compared to the consensus estimate of $21.43 million. During the same quarter last year, the firm earned ($0.17) EPS. The company’s revenue was up 159.6% on a year-over-year basis.
A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Guggenheim assumed coverage on shares of Sangamo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $18.00 price target on the stock. ValuEngine cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 6th. Finally, Wedbush restated a “hold” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $20.57.
In related news, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $14.55, for a total value of $72,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director H Stewart Parker acquired 2,000 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was acquired at an average cost of $13.52 per share, with a total value of $27,040.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 30,000 shares of company stock worth $434,950. Company insiders own 1.20% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Sangamo Therapeutics by 20.8% in the second quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock worth $114,780,000 after acquiring an additional 1,391,067 shares during the period. Wasatch Advisors Inc. lifted its stake in Sangamo Therapeutics by 9.9% in the second quarter. Wasatch Advisors Inc. now owns 4,058,167 shares of the biopharmaceutical company’s stock worth $57,626,000 after acquiring an additional 365,186 shares during the period. Northern Trust Corp lifted its stake in Sangamo Therapeutics by 21.0% in the second quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock worth $18,286,000 after acquiring an additional 223,870 shares during the period. Nexthera Capital LP lifted its stake in Sangamo Therapeutics by 35.7% in the second quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock worth $15,150,000 after acquiring an additional 280,538 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in Sangamo Therapeutics by 42.2% in the second quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after acquiring an additional 234,346 shares during the period. 63.84% of the stock is owned by institutional investors.
SGMO stock traded up $0.25 during mid-day trading on Friday, reaching $13.99. 186,785 shares of the stock traded hands, compared to its average volume of 2,285,163. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -19.99 and a beta of 2.97. Sangamo Therapeutics has a one year low of $11.30 and a one year high of $27.50.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Recommended Story: Fundamental Analysis – How It Helps Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.